IBB - iShares Nasdaq Biotechnology ETF

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
101.93
-1.96 (-1.89%)
At close: 4:00PM EST

101.99 +0.06 (0.06%)
After hours: 6:31PM EST

Stock chart is not supported by your current browser
Previous Close103.89
Open102.72
Bid101.51 x 800
Ask101.93 x 900
Day's Range101.70 - 103.65
52 Week Range100.22 - 122.97
Volume1,611,753
Avg. Volume2,030,728
Net Assets8.35B
NAV109.04
PE Ratio (TTM)3.54
Yield0.29%
YTD Return2.36%
Beta (3Y Monthly)1.63
Expense Ratio (net)0.47%
Inception Date2001-02-05
Trade prices are not sourced from all markets
  • Stocks finish lower after a volatile trading session
    Yahoo Finance Videolast month

    Stocks finish lower after a volatile trading session

    U.S. stocks snap a 3-day winning streak to wrap up a volatile trading week on Wall Street. Jared Blikre breaks down all the live market action from the floor of the New York Stock Exchange.

  • Newman: GOP still trying to kill the Affordable Care Act
    Yahoo Finance Videolast month

    Newman: GOP still trying to kill the Affordable Care Act

    Trump says the GOP will protect pre-existing conditions, but their actions say otherwise. Rick Newman on what's going on.

  • The Zacks Analyst Blog Highlights: Gilead Sciences, Alexion Pharmaceuticals, Regeneron Pharmaceutical and Biogen
    Zacks3 days ago

    The Zacks Analyst Blog Highlights: Gilead Sciences, Alexion Pharmaceuticals, Regeneron Pharmaceutical and Biogen

    The Zacks Analyst Blog Highlights: Gilead Sciences, Alexion Pharmaceuticals, Regeneron Pharmaceutical and Biogen

  • InvestorPlace4 days ago

    IBB’s $100 Support Level Goes Back to 2017

    To receive further updates on this iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) trade as well as an alert when it’s time to take profits, sign up for a risk-free trial of Maximum Options today. This morning I am recommending a bullish trade on the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB).

  • MarketWatch7 days ago

    Shares of Moderna open at $22, 4% lower than IPO price

    Shares of Moderna Inc. opened at $22 Friday on the Nasdaq , or 4% below its initial public offering price, with the first trade crossing at 11:40 am Eastern for 2,249,704 shares. The IPO priced on Thursday at the middle of the company's expected range of $22 to $24 a share. Moderna sold 26.3 million shares to raise $604.3 million, the largest biotech offering to date. The company has gone public during a sluggish time for biotech stocks; the Nasdaq Biotechnology ETF was up 14% for the year through August, but is now down 0.4% in the year to date. The S&P 500 is up 0.4%.

  • MarketWatch10 days ago

    Revance Therapeutics reaches licensing agreement with Fosun Pharmaceutical over botox formulation RT002

    Shares of Revance Therapeutics Inc. were up 1.9% in premarket trade Tuesday after the company announced it had entered an agreement with Shanghai Fosun Pharmaceutical Industrial Development Co. to give Fosun exclusive rights to develop and commercialize Revance's botulinum toxin formulation RT002 in mainland China, Hong Kong and Macau. Under the licensing agreement, Revance will receive an upfront payment of $30 million and is eligible to receive up to an additional $230.5 million in future development and sales milestone payments, as well as royalties on future net sales. Shares of Revance have fallen 42% in the year to date, while the iShares Nasdaq Biotechnology exchange traded fund has gained 3.3%. The SPDR S&P Biotech ETF, which includes smaller biotech companies, has fallen 0.3%, and the S&P 500 has advanced 4.4%.

  • MarketWatch19 days ago

    Zafgen's IND for diabetes treatment placed on hold by FDA

    Zafgen Inc. said Monday the Food and Drug Administration ha placed a clinical hold on its investigational new drug application (IND) for the biopharmaceutical company's first U.S. clinical trial of its type 2 diabetes treatment, citing the possibility of cardiovascular safety risk. The stock was halted for news until 7:30 a.m. Eastern. The FDA outlined multiple potential paths for moving forward, including nonclinical and clinical options to address the concerns. Zafgen said it plans to assess the options and request a Type A meeting with the FDA. Zafgen said that with the delay of additional clinical development for ZGN-1061, the company now expects its cash runway to extend through 2020. The stock has soared 97% year to date, while the iShares Nasdaq Biotechnology ETF has slipped 3.3% and the S&P 500 has lost 1.5%.

  • InvestorPlace23 days ago

    Pfizer Stock Has Multiple Positive Catalysts

    The stock market correction that started in October and has continued in November will encourage investors to buy more conservative stocks. Conversely, Pfizer Inc. (NYSE: PFE) stock is closer to its 52-week highs. Plus, Pfizer stock has a dividend yield of around 3%.

  • 7 Biotech ETFs to Consider for 2019
    InvestorPlace24 days ago

    7 Biotech ETFs to Consider for 2019

  • uniQure Stock Rose 35.7% Yesterday—Here’s Why
    Market Realist28 days ago

    uniQure Stock Rose 35.7% Yesterday—Here’s Why

    On November 15, uniQure (QURE) stock closed at $30.93, which reflected a ~35.66% rise from its previous day’s close of $22.80.

  • Drug prices may be rising, but you can buy biotech stocks at rock-bottom levels
    MarketWatchlast month

    Drug prices may be rising, but you can buy biotech stocks at rock-bottom levels

    Consider Gilead Sciences (GILD) and Celgene (CELG) for example. At recent prices of $70 and $75, they traded at market values that aren’t too far above the value of their operating businesses, according to discounted cash flow analysis by Jefferies biotech analyst Michael Yee and his team. Then add if they fall back to their “free pipeline” stock prices.

  • Jazz Pharmaceuticals: A Financial Overview in November
    Market Realistlast month

    Jazz Pharmaceuticals: A Financial Overview in November

    Jazz Pharmaceuticals generated revenues of $469.4 million in the third quarter, which reflects ~14% YoY (year-over-year) growth. Jazz Pharmaceuticals’ net revenues over the first nine months of 2018 were $1.4 billion—compared to $1.2 billion in the same period in 2017, which reflects ~20% YoY growth.

  • Benzingalast month

    The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs

    Earnings and U.S. midterm polls continued to positively influence biotech stocks, with the sector notching gains for the second straight week. These are some of the upcoming week's catalysts that could ...

  • How Marijuana-Focused Biotech Companies Have Performed in 2018
    Market Realistlast month

    How Marijuana-Focused Biotech Companies Have Performed in 2018

    Exploring Marijuana-Focused Biotech Companies' 2018 PerformancesMarijuana-focused biotech companies

  • Trump was Wrong about the Market
    Market Realistlast month

    Trump was Wrong about the Market

    Voting for Democrats was spectacular! A few weeks ago, we told investors that you really wanted to see the Democrats take the House.  That way, we would get gridlock and a check on the president, maybe even some help with tariffs. Well, initially this looks to be right.  The Dow Jones Industrials (DIA) are up 2% along with the S&P 500 (SPX), while the Nasdaq (QQQ) is up 2.5%.  So far, so good.

  • MarketWatchlast month

    MiMedx stock plunges after receiving delisting notice from Nasdaq

    Shares of MiMedx Group Inc. plummeted 34% to pace all Nasdaq losers in morning trade Wednesday, after the biopharmaceutical company disclosed that the Nasdaq will suspend trading in its stock starting Nov. 8, ahead of a delisting. The delisting notice comes as the company has failed to regain compliance with Securities and Exchange Commission reporting obligations amid an internal accounting investigation. Separately, the company said it has adopted a shareholder rights plan, also known as a "poison pill," that becomes exercisable of an investor acquires ownership of 10% or more of MiMedx common stock, in an effort to block an unsolicited buyout attempt. The stock has now lost 67% year to date, while the iShares Nasdaq Biotechnology ETF has gained 2.4% and the S&P 500 has advanced 3.9%.

  • How Exelixis’s Cabozantinib Franchise Is Positioned in November
    Market Realistlast month

    How Exelixis’s Cabozantinib Franchise Is Positioned in November

    In the third quarter, Exelixis’s (EXEL) Cabozantinib franchise generated revenues of $162.9 million, reflecting ~69% YoY growth. Exelixis’s Cabometyx generated revenues of $158.3 million in the third quarter, reflecting ~75% YoY growth.

  • MarketWatchlast month

    Puma Biotechnology's stock plunges to pace premarket losers after key drug Nerlynx disappoints

    Shares of Puma Biotechnology Inc. plummeted 38% toward a 2 1/2-year low, to pace all premarket decliners, after the company reported third-quarter earnings and revenue that beat expectations, but reported disappointing results of its key product, the breast cancer treatment Nerlynx. That prompted J.P. Morgan to swing to bearish from bullish and slash its stock price target. Total revenue rose to $62.6 million from $6.1 million a year ago, topping the FactSet consensus of $57.9 million, but Nerlynx sales of $52.6 million was below expectations of $58.1 million. The company said late Thursday on the post-earnings conference call with analysts that the percentage of patients who discontinued the use of Nerlynx because of adverse events increased to about 18%. J.P. Morgan's Cory Kasimov downgraded Puma to underweight from overweight and cut his price target to $23 from $83. "There simply doesn't appear to be enough new patient starts to offset the discontinuations and patients rolling off [Nerlynx] therapy after 12 months," Kasimov wrote in a note to clients. the stock had already tumbled 61% year to date through Thursday, while the iShares Nasdaq Biotechnology ETF has gained 1.2% and the S&P 500 had tacked on 2.5%.

  • Investor's Business Dailylast month

    Small Cap Stocks, Chips Lead Broad Gains, But This Group Surprisingly Lags

    The market extended its rebound Thursday as small cap stocks took the lead in a broad advance, but leading stocks again lagged.

  • Why Incyte’s Q3 2018 Earnings Beat Revenue Estimates
    Market Realistlast month

    Why Incyte’s Q3 2018 Earnings Beat Revenue Estimates

    Incyte (INCY) released its Q3 2018 earnings today. The company beat Wall Street analysts’ estimates for revenue but missed estimates for EPS. It reported EPS of $0.14 on revenues of $449.68 million in the third quarter of 2018, compared to estimates for EPS of $0.40 on revenues of $449.20 million.

  • Shire’s Q3 2018 Earnings: Analyst Estimates
    Market Realist2 months ago

    Shire’s Q3 2018 Earnings: Analyst Estimates

    Shire (SHPG) is a biotechnology company focused on discovering, developing, and commercializing specialty medicines to treat rare diseases and other specialized conditions. Shire is set to release its third quarter of 2018 earnings on November 1. Wall Street analysts estimate EPS of $3.58 on revenues of $3.82 billion.